Antibody response against SARS-CoV-2 in convalescent plasma donors: Can we predict subjects' eligibility?

Autor:	Prudente TP; Faculdade de Medicina da Universidade Federal de Goiás (FM-UFG), Goiânia, GO, Brazil. Electronic address: tiagopp27@gmail.com., Castro RG; Faculdade de Medicina da Universidade Federal de Goiás (FM-UFG), Goiânia, GO, Brazil., Candido MA; Faculdade de Medicina da Universidade Federal de Goiás (FM-UFG), Goiânia, GO, Brazil., Rodrigues RL; Faculdade de Medicina da Universidade Federal de Goiás (FM-UFG), Goiânia, GO, Brazil., de Souza LM; Hemocentro de Goiás (HEMOGO), Goiânia, GO, Brazil., Roberti MDRF; Faculdade de Medicina da Universidade Federal de Goiás (FM-UFG), Goiânia, GO, Brazil; Hemocentro de Goiás (HEMOGO), Goiânia, GO, Brazil.
Jazyk:	angličtina
Zdroj:	Hematology, transfusion and cell therapy [Hematol Transfus Cell Ther] 2022 Jan-Mar; Vol. 44 (1), pp. 1-6. Date of Electronic Publication: 2021 Nov 04.
DOI:	10.1016/j.htct.2021.07.008
Abstrakt:	Introduction: As the Coronavirus Disease 2019 (COVID-19) pandemic unfolds around the world; answers related to the antibody response against the virus are necessary to develop treatment and prophylactic strategies. We attempted to understand part of the immune response of convalescent plasma donation candidates. Method: We carried out a cross-sectional, observational, non-intervention study, testing 102 convalescent plasma donation candidates for antibodies against the virus, relating these data to the time interval between symptom onset and sample collection, age, disease severity, and gender. Results: In our sample, the individuals who developed a greater antibody response were the ones who had a longer time interval between symptom onset and sample collection, the ones who had been hospitalized and the subjects above 35 years old. Moreover, 17 individuals did not present any reactive antibodies. Conclusion: These results are important in that they raise questions about the role of the humoral response against the virus, as some individuals do not develop antibodies to fight it. In addition, they help develop recruitment strategies for convalescent plasma donors, who should be asymptomatic for at least 21 days and are possibly more likely to have reactive antibodies after 35 days without symptoms. Competing Interests: None. (© 2021 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu